Sunshine Biopharma Inc. (NASDAQ:SBFM) has announced pricing for a public offering expected to produce approximately $6.0 million in gross proceeds. The offering is being conducted on a reasonable best efforts basis, and the expected proceeds are stated before placement agent fees and other offering expenses payable by the company.
#Offering structure and pricing
The transaction covers 10,909,083 Common Units or Pre-Funded Units. Each unit includes either one share of Common Stock or one Pre-Funded Warrant, along with two Series D Warrants. Each Series D Warrant provides for the purchase of one share of Common Stock.
The public offering price is $0.55 per Common Unit. The price for each Pre-Funded Unit is $0.54999, reflecting the public offering price per Common Unit less the $0.00001 per-share exercise price under the Pre-Funded Warrants.
The Pre-Funded Warrants are immediately exercisable and remain exercisable until they have been exercised in full. The Series D Warrants are also immediately exercisable and expire five years after their initial issuance date. Their initial exercise price is $0.66.
The exercise price and the number of shares issuable under the Series D Warrants may be adjusted as set out in greater detail in the final prospectus to be filed for the offering. Further terms apply.
#Expected closing and use of proceeds
Sunshine Biopharma expects the transaction to close on or about October 9, 2026, subject to the satisfaction of customary closing conditions. The company expects to allocate the net proceeds to general corporate purposes and working capital.
Aegis Capital Corp. is serving as the exclusive placement agent. Sichenzia Ross Ference Carmel LLP is counsel to Sunshine Biopharma, while Kaufman & Canoles, P.C. is counsel to Aegis Capital Corp.
#Regulatory status
The U.S. Securities and Exchange Commission declared effective on October 7, 2026 a Form S-1 registration statement, No. 333-299274, that Sunshine Biopharma had filed on October 2, 2026.
The securities are being offered only through a prospectus. The company said a final prospectus will be filed with the SEC. The offering does not constitute an offer to sell or a solicitation of an offer to buy, and the securities may not be sold in a state or jurisdiction where such activity would be unlawful before registration or qualification under applicable securities laws.
#Sunshine Biopharma’s business
Sunshine Biopharma develops generic and specialty prescription medicines, with products that include treatments in oncology and antivirals. The company says it currently has 61 generic prescription drugs on the market in Canada and approximately 11 additional drugs expected to be launched in the remainder of 2026.
Its proprietary development programme includes K1.1 mRNA, described as an mRNA-Lipid Nanoparticle targeted for liver cancer, and a PLpro protease inhibitor, a small-molecule treatment for SARS Coronavirus infections.
#Key Takeaways
- Sunshine Biopharma announced pricing for a public offering with gross proceeds expected to be approximately $6.0 million before fees and other offering expenses.
- The offering comprises 10,909,083 Common Units or Pre-Funded Units priced at $0.55 or $0.54999, respectively.
- Each unit includes one share or one Pre-Funded Warrant and two Series D Warrants, with the Series D Warrants carrying an initial exercise price of $0.66.
- The transaction is expected to close on or about October 9, 2026, subject to customary closing conditions.
- The SEC declared the related Form S-1 registration statement effective on October 7, 2026, while a final prospectus remains to be filed.
Original source: Read original article